Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITHACA trial of AMY-101 in severe COVID-19 with ARDS
2020-004408-32Phase 2Terminated
- Sponsor
- Amyndas Pharmaceuticals
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing AMY-101 with Placebo (2 arms). Primary endpoint: Survival without ARDS and without oxygen requirement at day 14. Started Oct 2020; status: terminated.
02
Drugs
AMY-101
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-004408-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004408-32.